GP-PHC-GP 22/1





Gary Payton 22/1

Cannabis Based Medicinal Product (CBMP)
Approved for prescription use in the UK.

Transcription: GP-PHC-GP

Grown by: PHCann in North Macedonia

Active ingredient: Approx. 22% THC

<1% CBD

Profile Type: Hybrid

Cultivar: Gary Payton

Formulation: Flos: whole dried Cannabis

Flowers

Ingestion method: Inhaled via herbal

vaporiser



Ingredients:	Most prevaler terpenes:	alpha-Terpine 5.5%	eol:
% 30 -	Linalool: 22.4%		200
25 - 20 - 15 -	Fenchol: 5.4%	Total Terpene Content: 3.06%	β-Caryophyllene: 37.6%
5 - THC CBD	d-Limonene: 19.3%		β-Myrcene: 6.2%

Terpene	B-Carophyllene	Linalool	D-Limonene	B-Mycrene
Scent	sweet	floral	orange	spicy
	peppery	citrus	citrus	earthy

GP-PHC-GP 22/1

TITRATION GUIDE

- There currently is no uniform starting dose for cannabis products nor uniform dosing information.
- Patients are recommended to slowly titrate up to find their optimal dose for maximal therapeutic effects and minimal adverse effects.
- Timing of onset depends on mode of administration.

Onset and duration of effects for inhalation and oral adminstration²

	Inhalation		Oral administration		
Onset of Effect	<u>.</u>	Within seconds to minutes	(L)	Within 30 minutes to 2 hours	
Peak effects	Ŀ	Full effects peak within 30 minutes	Ŀ	Full effects peak within 4 hours	
Duration of Effect	(L)	Up to 6 hours or longer	Ŀ	Up to 12 hours or longer	

^{2.} Minister of Health HC, Health Canada. Health Effects of Cannabis.; 2017.

Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard

Adverse events should also be reported to:

IPS Pharma | medicalcannabis@ipsspecials.com | 0800 644 0747



Grow Group | Eastcastle House, 27/28 Eastcastle St, London W1W 8DH | United Kingdom